Related Experiment Video
Updated: Mar 17, 2026
Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development
Published on: October 30, 2013
Progress and challenges in CAR-T cell therapy for bladder cancer
Kun Zhao1, Zhongze Zhou1, Xueming Ma1
1Department of Urology, the Second Hospital of Lanzhou University, Lanzhou, Gansu 730000, China; The Second Hospital & Clinical Medical School, Lanzhou University, Lanzhou, Gansu 730000, China; Gansu Province Clinical Research Center for urinary system disease, Lanzhou, Gansu 730000, China.
Chimeric antigen receptor T-cell (CAR-T) therapy shows promise for bladder cancer (BC) treatment, offering new hope for advanced cases. Further research is needed to overcome challenges like target selection and the tumor microenvironment for broader clinical use.
Area of Science:
- Oncology
- Immunotherapy
- Urology
Background:
- Bladder cancer (BC) is a widespread urinary system malignancy with increasing incidence globally.
- Advanced and metastatic BC present significant treatment challenges.
- Chimeric antigen receptor T-cell (CAR-T) immunotherapy, successful in blood cancers, is being investigated for solid tumors like BC.
Purpose of the Study:
- To review recent advancements in CAR-T cell therapy for bladder cancer.
- To focus on therapeutic targets, mechanisms of action, and combination strategies.
- To discuss preclinical and early-phase clinical trial findings.
Main Methods:
- Literature review of preclinical studies and early-phase clinical trials on CAR-T therapy for BC.
- Analysis of therapeutic targets, mechanisms, and combination strategies.
- Evaluation of current evidence on CAR-T efficacy and challenges in BC.
Main Results:
- CAR-T therapy demonstrates promising antitumor activity in preclinical and early clinical bladder cancer studies.
- Key challenges identified include optimal target selection, overcoming the immunosuppressive tumor microenvironment (TME), and the need for more clinical validation.
- Current evidence suggests CAR-T therapy is a viable avenue for BC treatment.
Conclusions:
- CAR-T cell therapy holds significant potential for treating bladder cancer, particularly advanced stages.
- Addressing challenges such as target specificity and the TME is crucial for successful clinical translation.
- Future translational and clinical studies are essential to fully validate CAR-T therapy for BC.
